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The endocannabinoid system (ECS) controls energy balance by regulating both
energy intake and energy expenditure. Endocannabinoid levels are elevated in obesity
suggesting a potential causal relationship. This study aimed to elucidate the rate
of dysregulation of the ECS, and the metabolic organs involved, in diet-induced
obesity. Eight groups of age-matched male C57Bl/6J mice were randomized to
receive a chow diet (control) or receive a high fat diet (HFD, 45% of calories
derived from fat) ranging from 1 day up to 18 weeks before euthanasia. Plasma
levels of the endocannabinoids 2-arachidonoylglycerol (2-AG) and anandamide (N-
arachidonoylethanolamine, AEA), and related N-acylethanolamines, were quantified by
UPLC-MS/MS and gene expression of components of the ECS was determined in
liver, muscle, white adipose tissue (WAT) and brown adipose tissue (BAT) during the
course of diet-induced obesity development. HFD feeding gradually increased 2-AG
(+132% within 4 weeks, P < 0.05), accompanied by upregulated expression of its
synthesizing enzymes Daglα and β in WAT and BAT. HFD also rapidly increased
AEA (+81% within 1 week, P < 0.01), accompanied by increased expression of its
synthesizing enzyme Nape-pld, specifically in BAT. Interestingly, Nape-pld expression in
BAT correlated with plasma AEA levels (R2 = 0.171, β = 0.276, P < 0.001). We conclude
that a HFD rapidly activates adipose tissue depots to increase the synthesis pathways
of endocannabinoids that may aggravate the development of HFD-induced obesity.
Keywords: brown adipose tissue, white adipose tissue, diet-induced obesity, endocannabinoids, NAPE-PLD
Abbreviations: 2-AG, 2-arachidonoylglycerol; AA, arachidonic acid; ABHD4, Abhd4 Alpha/beta hydrolase domain
containing-4; AEA, anandamide (N-arachidonoylethanolamine); BAT, brown adipose tissue; CB1R, cannabinoid
receptor type 1; CB2R, cannabinoid receptor type 2; DAGL-α/β, Dagl-α/β diacylglycerol lipase-α/β; DEA,
N-docosatetraenoylethanolamine; DIO, diet-induced obesity; ECS, endocannabinoid system; FAAH, Faah fatty acid
amide hydrolase; GDE1, Gde1 glycerophosphodiesterase-1; gWAT, gonadal white adipose tissue; HFD, high fat diet;
LC-MS/MS, liquid chromatography coupled tandem mass spectrometry; MAGL, Mgll monoacylglycerol lipase; NAE,
N-acylethanolamine; NAPE, N-acylphosphatidylethanolamine; NAPE-PLD, Nape-pld N-acylphosphatidylethanolamine
phospholipase D; OEA, N-oleoylethanolamine; PEA, N-palmitoylethanolamine; SEA, N-stearoylethanolamine.
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INTRODUCTION
Obesity is becoming a global epidemic and the need for
development of novel therapeutic interventions is high. The
endocannabinoid system (ECS) is regarded as a potential
therapeutic target since it regulates energy balance by influencing
appetite (Foltin et al., 1988; Jamshidi and Taylor, 2001),
intracellular lipolysis and energy expenditure [reviewed in (Cota,
2007; Mazier et al., 2015)]. The ECS consists of cannabinoid
receptors, their endogenous ligands, the endocannabinoids, and
the enzymes that synthesize and degrade the endocannabinoids.
The cannabinoid receptors are G-protein-coupled receptors,
comprising the CB1R and CB2R. The CB1R is expressed
centrally and in peripheral metabolic tissues including
white adipose tissue (WAT), brown adipose tissue (BAT),
liver, skeletal muscle and the pancreas. In contrast, the
CB2R is mainly expressed in immune cells (Howlett et al.,
2002).
The two main circulating endocannabinoids are
anandamide (N-arachidonoylethanolamine, AEA) and
2-arachidonoylglycerol (2-AG). Although they are both
derived from cell membrane arachidonic acid (AA) derivatives,
the levels of these endocannabinoids are differentially
regulated. AEA can be generated via hydrolysis of N-acyl-
phosphatidylethanolamines (NAPE) by a NAPE-specific
phospholipase D (NAPE-PLD) and its degradation is
primarily regulated by fatty acid amide hydrolase (FAAH).
2-AG levels are regulated by the biosynthesis enzymes
diacylglycerol lipase α and β (DAGL-α and β) and the
degradation enzyme mono-acylglycerol lipase (MAGL)
(Muccioli, 2010; Bisogno and Maccarrone, 2014; Baggelaar
et al., 2018).
Activation of the CB1R in peripheral tissues inhibits fatty
acid oxidation resulting in a positive energy balance and thus
development of obesity in mice (Ravinet Trillou et al., 2003;
Osei-Hyiaman et al., 2005; Arrabal et al., 2015). In addition,
an increased tone of the ECS is associated with obesity in
humans (Engeli et al., 2005; Bluher et al., 2006). Efforts have
been made to reverse obesity by blocking the CB1R by small
molecules such as the inverse agonist rimonabant (Sam et al.,
2011). Albeit that rimonabant was effective in humans as evident
from sustained weight loss and reduction of dyslipidaemia,
centrally mediated side effects resulted in removal from the
market (Despres et al., 2005; Pi-Sunyer et al., 2006). Nevertheless,
blocking the actions of the ECS is still regarded a potent
therapeutic strategy [reviewed in (O’Keefe et al., 2014; Simon and
Cota, 2017)].
To develop novel therapeutics that target specific aspects
of the ECS, it is crucial to obtain more insight in how
fast and in which organs the dysregulation of the ECS sets
off. In this study, we aimed at elucidating these questions
by exposing mice to a high fat diet (HFD) ranging from
1 day up to 18 weeks, which finally causes diet-induced
obesity (DIO). We analyzed endocannabinoid levels in
plasma as well as the expression of enzymes involved in
endocannabinoid synthesis and breakdown in several metabolic
organs.
MATERIALS AND METHODS
Animals and Diet
Eighty-six 7-week old male C57B1/6J mice (Charles River
Laboratories, United States) were obtained. All mice were group
housed (3–4 mice per cage) under a 12 h:12 h light-dark cycle
with ad libitum access to food and water. During the course of
the experiment 7 out of 8 groups of mice were switched from
a regular chow diet (Special Diets Services, United Kingdom)
to a HFD (45% kcal fat, 35% kcal carbohydrate, 20% kcal
protein, Special Diets Services, United Kingdom) in such a way
that all mice were 25 weeks of age at the time of euthanasia.
In total, the study consisted of eight groups receiving HFD
for 0 day (control group, remaining on a regular chow diet),
1 day, 3 days, 1, 2, 4, 10, and 18 weeks (n = 10–11 per
group). At the end of the study, mice were fasted overnight
and subsequently euthanized by an injection with 0.25 mg
ketamine and 0.05 mg xylazine per gram body weight. Blood
was collected via a cardiac puncture with EDTA filled syringes
and several organs (liver, quadriceps muscle, gonadal WAT and
interscapular BAT) were isolated. The organs were immediately
snap frozen in liquid nitrogen and stored at −80◦C until further
analysis. For BAT, a small piece was fixated for histological
analysis. A second experiment was performed in which 14-
week old male C57Bl/6J mice (Charles River Laboratories,
United States) were fed 0 day or 1 week HFD (n = 8 per group)
prior to euthanasia. Mice were fasted for 4 h and euthanized
by CO2 suffocation. Blood was collected via cardiac puncture
with EDTA filled syringes as described above. These studies
were carried out in accordance with the recommendations of
the animal experimentation guidelines of Amsterdam Medical
Center (n = 86 experiment) and Leiden University Medical
Center (n = 16 experiment) and approved by the local ethical
review boards on animal experimentation.
Endocannabinoid Plasma Levels
A liquid-liquid extraction using methyl tert-butyl ether as
an organic solvent was used to extract endocannabinoids
from plasma. Levels of endocannabinoids (AEA, 2-AG),
N-acylethanolamines (NAEs), and AA were measured by UPLC-
MS/MS (AB Sciex 6500 QTRAP) in 25 µL plasma samples. From
the pool of individual study samples, quality controls (QCs) were
used to generate calibration curves. Additionally, all samples were
randomized and each batch of study samples included calibration
samples, an even distribution of QC samples and blanks. The
sample extraction procedure and method has been described in
detail previously (Kantae et al., 2017).
RNA Isolation and RT-PCR Analysis
RNA of liver and muscle was isolated using TriPure Isolation
reagent (Roche, Netherlands) and 1 µg of RNA was reverse
transcribed using Moloney Murine Leukemia Virus Reverse
Transcriptase (Promega, Netherlands). For WAT and BAT, RNA
was isolated using Trizol (Invitrogen, United States) and cDNA
was synthesized using an iScript cDNA synthesis kit (Bio-Rad,
Netherlands). RT-PCR was carried out on a CFX96 PCR machine
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(Bio-Rad) using IQ SYBR-Green Supermix (Promega). mRNA
expression was normalized to Hprt and 36b4 as household genes
for liver, BAT and WAT; for muscle mRNA expression was
normalized to the expression of 36b4 only. Changes in gene
expression relative to basal expression levels were only calculated
if the average expression of at least the control group were
Ct < 32. Primer sequences are listed in Table 1.
Histology and Determination of Lipid
Droplet Content in BAT
After dissection, a small piece of interscapular BAT was
immediately fixated in 4% paraformaldehyde, subsequently
dehydrated and embedded in paraffin. A Haematoxylin and
Eosin staining was performed on paraffin sections using standard
protocols. Intracellular lipid content was quantified with ImageJ
(version 1.49).
Statistical Analysis
All data are expressed as mean ± SEM. Data analysis was
performed with an IBM SPSS Statistics 23 software package.
Analysis between multiple groups was done by a one-way
ANOVA with Dunnett’s post hoc test. For the analysis of plasma
2-AG in the second experiment we used an unpaired two-
sided t-test. Furthermore, linear regression analysis computed
by Pearson’s correlation was used to determine correlations.
Significant differences are expressed relative to the chow-fed
(0 week HFD) control group.
RESULTS
HFD Feeding Rapidly Increases Plasma
2-AG and AEA Levels in Mice
To investigate the time course of the dysregulation of the ECS
in the development of DIO, C57B1/6J mice were fed a HFD for
1 day up to 18 weeks. As expected, dietary intervention increased
body weight (up to +51% after 18 weeks, P < 0.001, Table 2).
Blood glucose levels rapidly increased in response to the HFD
(+88% after 1 day of HFD, P < 0.001), whereas plasma TG
TABLE 1 | List of primer sequences for RT-PCR.
Gene Forward primer Reverse primer
Abhd4 ATCCTCCAGTGTCTCCAGAACAA GGGTCCCTTGGGAATGTTGG
Cd68 ATCCCCACCTGTCTCTCTCA TTGCATTTCCACAGCAGAAG
Daglα TATCTTCCTCTTCCTGCT CCATTTCGGCAATCATAC
Daglβ GGGTCTTTTGAGCTGTTC AAGGAGGACTATCAGGTA
Faah CAGCTACAAGGGCCATGCT TTCCACGGGTTCATGGTCTG
Gde1 AAGGATTTTGTCTCCCCGGAC ATGTAGCTGGACCCAAGGTG
Hprt TTGCTCGAGATGTCATGAAGGA AGCAGGTCAGCAAAGAACTTATAG
Mgll CAGAGAGGCCAACCTACTTT ATGCGCCCCAAGGTCATATTT
Nape-pld AAAACATCTCCATCCCGAA CGTCCATTTCCACCATCA
Pla/at1 CGGTAAATGATTGCTTCAGT CCACAACATCCTTCAAAAGC
Pla/at5 CCTGGAGACCTGATTGAGA GGTTGCTGAAGATAGAGGTG
36b4 GGACCCGAGAAGACCTCCTT GCACATCACTCAGAATTTCAATGG
levels increased more gradually (+155% after 2 weeks of HFD,
P < 0.01) (Table 2).
First, we assessed plasma levels of the two main
endocannabinoids in the course of DIO development (Figure 1).
HFD feeding gradually increased 2-AG levels, which reached
significance after 4 weeks (+132%, P < 0.05) and further
increased up to 18 weeks (+201%; P < 0.001) (Figure 1A).
Of note, in a few samples of the control group we observed
extremely high 2-AG levels (>100 pmol/mL) that masked
an initial increase in 2-AG levels upon HFD. To determine
whether these high levels would represent (biological) outliers,
we determined plasma 2-AG levels in a separate cohort of mice
fed a HFD for 0 or 7 days. Indeed these values lie more than
six standard deviations away from the average of the repeated
control animals and could therefore be regarded as biological
outliers. Importantly, we observed a trend toward elevated 2-AG
plasma levels in the 7 days HFD fed group (+34%, P = 0.055,
not shown) compared to the 0 day group in the repeated
experiment. Therefore, we excluded the mice of the control
group with extremely high plasma 2-AG levels from calculation
of the means of all endocannabinoids and related metabolites,
and instead indicated these data in gray (Figures 1A–I). HFD
feeding also rapidly increased levels of AEA, the other main
endocannabinoid, which reached significance after 1 week
(+81%, P < 0.01) and further increased up to 18 weeks
(+165%, P < 0.001) (Figure 1B). Next, we determined whether
plasma endocannabinoid levels were related to body weight.
Linear regression analysis on all data combined showed that
body weight correlated weakly but positively with 2-AG levels
(R2 = 0.073, β = 1.447, P = 0.017, Figure 1C) and much more
strongly with AEA levels (R2 = 0.654, β = 0.041, P < 0.001,
Figure 1D).
NAPE-PLD does not only produce AEA, but
generates a whole family of N-acylethanolamines
(NAEs), including N-oleoylethanolamine (OEA),
N-palmitoylethanolamine (PEA), N-stearoylethanolamine
(SEA), and N-docosatetraenoylethanolamine (DEA). Similar
to AEA, plasma concentrations of these non-cannabinoid fatty
acid amides were raised in response to HFD feeding, albeit
with different kinetics (Figures 1E–H). Plasma levels of AA, the
precursor and degradation product of 2-AG and AEA (Piomelli,
2003), also rapidly increased in the first 2 weeks of HFD after
which a plateau was reached (+89% after 18 weeks, P < 0.001,
Figure 1I). Of note, the samples of the control group with
extremely high 2-AG levels (Figure 1A) also showed elevated AA
levels (Figure 1I).
HFD Feeding Increases Expression of
2-AG Synthesis and Degradation
Enzymes in WAT and BAT
Next, we assessed gene expression of the enzymes responsible
for the synthesis (Daglα and Daglβ) and degradation (Mgll) of
2-AG in liver, muscle, WAT and BAT (Figure 2; an overview of
all relative gene expressions of the enzymes involved in synthesis
and degradation is shown in Supplementary Table S1). HFD
feeding transiently increased Daglα expression in WAT after
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TABLE 2 | General characteristics of the mice during diet-induced obesity development.
Duration of HFD (weeks), mean ± SEM
0 1/7 3/7 1 2 4 10 18
N= 11 11 10 10 11 11 11 11
Body weight (g) 27.3 ± 0.6 29.5 ± 0.6 31.1 ± 0.8∼ 31.5 ± 0.5∗ 34.4 ± 0.9∗∗∗ 36.5 ± 1.2∗∗∗ 38.1 ± 0.9∗∗∗ 41.3 ± 2.0∗∗∗
Glucose (mg/dL) 69 ± 3 130 ± 15∗∗∗ 118 ± 7∗∗∗ 123 ± 4∗∗∗ 104 ± 5∗ 91 ± 4 112 ± 9∗∗ 124 ± 7∗∗∗
Triglycerides (mM) 0.20 ± 0.02 0.25 ± 0.05 0.41 ± 0.09∼ 0.34 ± 0.06 0.51 ± 0.07∗∗ 0.81 ± 0.08∗∗∗ 0.54 ± 0.03∗∗ 0.60 ± 0.05∗∗∗
Values are indicated in mean ± SEM. ∼P < 0.1, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 compared to the control group. These data were previously published elsewhere
(van den Berg et al., 2016).
3 days (+57%, P < 0.05, Figure 2A) and increased Daglα
expression in BAT after 1 and 4 weeks of HFD (Figure 2B). HFD
feeding also induced Daglβ expression in WAT (Figure 2C) and
BAT (Figure 2D), especially toward the end of the intervention
(i.e., +246% in WAT and +38% in BAT after 18 weeks).
Linear regression analyses between the expression levels of
DAG lipases in adipose tissues and plasma 2-AG levels showed
inconclusive data (Supplementary Figure S1). HFD feeding
also transiently increased Mgll expression in WAT reaching
a peak after 1 week of HFD (+75%, P < 0.001), which
normalized toward the end of HFD intervention (Figure 2E). In
contrast, HFD induced a sustained increase in Mgll expression
levels in BAT from 1 day on (+28%, P < 0.05, Figure 2F).
HFD feeding did not persistently affect gene expression of
synthesis and degradation enzymes in liver and muscle. It only
temporarily increased Daglα expression in muscle (at 2 weeks),
increased Daglβ expression (at 3 days) and decreased Mgll
expression (at 1 day) in liver (data in Supplementary Table
S1). Collectively, these data show that the rise in 2-AG levels
during DIO development coincided with enhanced expression
of synthesis and degradation enzymes specifically in WAT and
BAT.
HFD Feeding Increases Nape-pld
Expression in WAT and BAT
We next assessed gene expression of the enzyme responsible for
AEA and NAEs synthesis (Nape-pld) in the various metabolic
organs. HFD feeding tended to increase Nape-pld expression
in WAT after 3 days, although expression levels normalized
thereafter and were decreased after 18 weeks (−41%, P < 0.01,
Figure 3A). Surprisingly, linear regression analysis showed
a small, but significant, negative correlation between Nape-
pld expression in WAT and plasma AEA levels (R2 = 0.124,
β = −0.235, P = 0.002, Figure 3B). Interestingly, HFD feeding
increased Nape-pld expression in BAT starting at 3 days (+102%,
P < 0.001, Figure 3C), after which levels reached a plateau.
Moreover, Nape-pld expression in BAT positively correlated with
plasma AEA levels (R2 = 0.171, β = 0.276, P < 0.001, Figure 3D),
supporting a contribution of BAT Nape-pld expression to
circulating AEA levels. HFD feeding decreased the expression
of Nape-pld in muscle reaching significance from 4 weeks
onwards and did not affect Nape-pld expression in de liver
(data in Supplementary Table S1). We also determined the
potential contribution of the expression of genes involved in
the phospholipase A/acyltransferase (PLA/AT) family, which
can produce NAPE in a Ca2+-independent manner, in the
increase in AEA levels in DIO (Hussain et al., 2017). However,
expression of the PLA/AT (HRAS-like suppressor) gene family
was either too low to detect (Pla/at1 in liver, WAT, BAT and
Pla/at5 in liver) or did not show a clear or persistent rise in
expression levels that could explain the rise in AEA levels (not
shown). Alpha/beta hydrolase domain containing-4 (ABHD4)
and glycerophosphodiesterase-1 (GDE1) have been suggested
to be involved in AEA synthesis by BAT (Krott et al., 2016).
However, time-dependent expression levels of Abhd4 and Gde1
in BAT did not coincide with the HFD-induced rise in AEA and
NAEs (not shown).
Next, we determined gene expression levels of Faah, the
enzyme involved in AEA and NAEs degradation. HFD feeding
decreased Faah expression levels in the liver after 18 weeks
(−41%, P < 0.01, Supplementary Table S1). Expression levels
of Faah in muscle, WAT and BAT were too low to be detected.
Altogether, these data show that HFD robustly increased the
expression of Nape-pld in BAT, suggesting that this tissue may
contribute to the increased plasma AEA and NAE levels during
DIO development.
Plasma AEA Levels Positively Correlate
With Lipid Content of BAT
Next, we aimed to gain more insight into the cell types within
BAT that may have contributed to the robust increased Nape-
pld expression and plasma AEA levels in DIO development.
Because macrophages have been shown to produce AEA
(Di Marzo et al., 1996), we first determined gene expression levels
of the macrophage marker Cd68 in BAT. Linear regression
analysis showed a weak positive correlation between Cd68
expression and Nape-pld expression in BAT (R2 = 0.113,
β = 0.170, P = 0.002, Figure 4A) and plasma AEA levels
(R2 = 0.088, β = 0.088, P = 0.009, Figure 4B). Besides
macrophages, brown adipocytes might also be involved. Since
intracellular lipid droplets have been shown to co-localize with
intracellular AEA (Oddi et al., 2008), we quantified BAT lipid
droplet content in H&E stained BAT sections (Supplementary
Figure S2). Compared toCd68, BAT lipid droplet content showed
a more pronounced positive correlation withNape-pld expression
levels in BAT (R2 = 0.385, β = 0.021, P < 0.001, Figure 4C) as
well as plasma AEA levels (R2 = 0.172, β = 0.010, P < 0.001,
Figure 4D).
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FIGURE 1 | High fat diet feeding time-dependently increases plasma levels of 2-AG and AEA in mice. Liquid chromatography coupled with tandem mass
spectrometry (LC-MS/MS) was used to determine plasma levels of 2-AG (A), AEA (B), OEA (E), PEA (F), SEA (G), DEA (H), and AA (I). Data are mean ± SEM
(n = 10–11). Error bars were too small to be visible for several data points (in A,E–G,I). ∼P < 0.1, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 compared to the control
(0 week of HFD) group analyzed by one-way ANOVA with Dunnett’s post hoc test. In addition, linear regression analysis was performed on correlations between
body weight and plasma levels of 2-AG (C) or AEA (D), for all samples depicted in black (n = 81). Samples depicted in gray were regarded as biological outliers
based on 2-AG and AA levels and therefore excluded from plasma data analyses.
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FIGURE 2 | High fat diet (HFD) feeding increases the expression of 2-AG
synthesis and degradation enzymes in WAT and BAT. Relative gene
expression of 2-AG synthesis enzymes Daglα (A,B), Daglβ (C,D), and
degradation enzyme Mgll (E,F) in WAT (A,C,E) and in BAT (B,D,F). The
number in the column of the 0 week of HFD group indicates the average CT
value of that treatment group for that gene. Data are mean + upper SEM
(n = 10–11) ∼P < 0.1, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 compared to the
control (0 week of HFD) group analyzed by one-way ANOVA with Dunnett’s
post hoc test.
DISCUSSION
In this study, we demonstrated that HFD feeding increases
circulating levels of endocannabinoids, with a rapid initial
increase in AEA and a more gradual increase in 2-AG, in the
course of DIO development. These changes were accompanied
by increased gene expression of the synthesis and degradation
enzymes of 2-AG in both WAT and BAT, and with increased
expression of the AEA synthesis enzyme Nape-pld in BAT. Taken
together, these data indicate that the dysregulation of the ECS in
the development of obesity occurs rapidly and that WAT and BAT
might contribute to these effects.
The observed increases in endocannabinoids in the
development of DIO are in agreement with previous studies
in mice that showed increased plasma 2-AG and AEA levels
after 9 weeks (D’Eon et al., 2008) and 36 weeks (Pati et al.,
2018) of HFD feeding and increased plasma AEA levels in a
model for glucocorticoid induced obesity (Bowles et al., 2015).
These data also are concordant with data in humans, since
obese individuals have higher 2-AG levels compared to lean
FIGURE 3 | High fat diet feeding upregulates Nape-pld expression in WAT
and in BAT. Relative gene expression of AEA synthesis enzyme Nape-pld in
WAT (A), BAT (C). The number in the column of the 0 week of HFD group
indicates the average CT value of that treatment group for that gene. Data are
mean + upper SEM (n = 10–11). ∗∗P < 0.01, ∗∗∗P < 0.001 compared to the
control (0 week of HFD) group analyzed by one-way ANOVA with Dunnett’s
post hoc test. In addition, linear regression analysis was performed on
correlations between Nape-pld expression relative to 0 week of HFD in WAT
(B) or in BAT (D) and plasma levels of AEA, for all samples depicted in black
(n = 81). Samples depicted in gray were regarded as biological outliers based
on 2-AG and AA levels and therefore excluded from linear regression
analyses.
individuals (Engeli et al., 2005; Bluher et al., 2006; Cote et al.,
2007). It was somewhat surprising that a subset of the control
group that were not fed a HFD showed very high 2-AG levels in
addition to AA levels, the reason of which is currently unclear
to us. By performing a second study in mice we confirmed that
HFD feeding induced an initial rise rather than decrease in 2-AG
levels. Thus, although the reason for the very high 2-AG levels
in a subgroup is intriguing, we regarded those mice as biological
outliers. Besides 2-AG and AEA, HFD feeding also increased the
plasma levels of AA. Since AA is constituent and degradation
product of 2-AG and AEA, elevated AA levels may either be
a cause or consequence of the increased levels. HFD feeding
also increased plasma levels of other N-acylethanolamines,
including OEA, PEA, SEA and DEA. These NAEs have other
biological targets involved in controlling the energy balance,
such as peroxisome proliferator-activated receptors-α (PPARα),
PPARγ and G protein-coupled receptor 119 (Fezza et al.,
2014).
Currently, it is unknown which organs contribute to the
increased plasma endocannabinoid levels in HFD-induced
obesity (Hillard, 2018). We showed that body weight positively
correlates with plasma endocannabinoid levels, albeit that the
correlation with AEA (R2 = 0.654) is stronger than with 2-AG
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FIGURE 4 | Both macrophage marker expression in BAT and lipid content of
BAT positively correlate with plasma AEA levels. Linear regression analysis
was performed on correlations between Cd68 expression relative to 0 week of
HFD in BAT and Nape-pld expression in BAT (A) or plasma levels of AEA (B).
Also, linear regression analysis was performed on correlations between lipid
content of BAT and Nape-pld expression relative to 0 week of HFD in BAT (C)
or plasma levels of AEA (D). Correlations are shown for all samples depicted
in black (n = 86 in A,C and n = 81 in B,D). Samples depicted in gray were
regarded as biological outliers based on 2-AG and AA levels and therefore
excluded from linear regression analyses.
(R2 = 0.073). Since body weight differences in the range of
approximately 30–50 g, as observed in this study, are mainly
caused by differences in body fat (van Beek et al., 2015), it was
considered likely that engulfment of lipids by adipocytes and/or
expansion of the adipocyte pool would contribute to the increase
in endocannabinoids. Insulin resistance, which is closely linked
to increased intracellular lipid deposition (Tchernof and Despres,
2013) is also associated with a dysregulated ECS (Gruden et al.,
2016). By performing gene expression analysis in metabolically
active organs, we could demonstrate that expression of enzymes
involved in endocannabinoid synthesis increased in WAT as
well as BAT. This is in full agreement with a previous study
in which 3 and 8 weeks of HFD feeding, with a diet closely
resembling the HFD used in our experiments, resulted in
increased local levels of endocannabinoids (AEA and 2-AG)
in BAT (Matias et al., 2008). The increase in plasma 2-AG
coincided with increased gene expression of DAGLα and DAGLβ
in both WAT and BAT. Given the different time-course of
expression, where the increase in Daglα seems to precede the
increase in Daglβ, we postulate that DAGLα may be responsible
for the initial rise in 2-AG, while DAGLβ may mediate the
late increase in 2-AG. Similarly, the increase in plasma AEA
coincided with increased gene expression of its synthesizing
enzyme NAPE-PLD in BAT. Moreover, plasma AEA correlated
positively with Nape-pld expression in BAT but not in WAT.
It is therefore likely that BAT rather than WAT contributes
to the rise in AEA levels. In this respect, it is interesting that
expression of Nape-pld is higher in BAT than in WAT, as
evident from lower Ct values. The expression levels of most
of the enzymes showed a sharp increase in the first week of
HFD feeding, which coincided with the timing of the largest
increase in lipid deposition in BAT. In BAT, ABHD4, and GDE1
were shown to also be involved in AEA synthesis and their
expression respond to BAT activating agents (Krott et al., 2016),
although we did not find the expression levels of these enzymes
to coincide with the increase in circulating AEA and NAEs
levels with prolonged HFD feeding. Of note, expression of the
endocannabinoid degradation enzymes Faah and Mgll in the
adipose tissues were either undetectable or increased. Although
we have not been able to measure actual enzyme activities due to
technical reasons, it is tempting to speculate that net whole body
endocannabinoid synthesis exceeds degradation since circulating
levels increase in the course of DIO. Synthesis enzymes of 2-
AG in liver and skeletal muscle were only transiently increased,
and the synthesis enzyme of AEA was decreased in skeletal
muscle. Thus, although we cannot exclude the contribution of
other organs as source for plasma endocannabinoid levels (e.g.,
brain and intestine), our data suggest that WAT and BAT are
likely important organs that release 2-AG and AEA levels in
HFD-induced obesity.
It is interesting to speculate on the cellular source within the
adipose tissue depots that is involved in endocannabinoid
synthesis. HFD-induced development of DIO causes
accumulation of macrophages in WAT (van Beek et al.,
2015) as well as BAT (Van den Berg S. M., unpublished).
Macrophages are able to produce AEA (Di Marzo et al., 1996),
and we found a positive correlation between macrophage marker
Cd68 and Nape-pld expression in BAT as well as with AEA
levels in plasma. However, the concentration of macrophages
in adipose tissue is relatively low, even in obesity, and stronger
positive correlations were found between the lipid content in
BAT and both Nape-pld expression and plasma AEA levels.
Therefore, adipocytes likely contribute substantially more to
the circulating endocannabinoid pool than macrophages. This
hypothesis is corroborated by previous findings that AEA co-
localizes with adiposomes or lipid droplets in vitro (Oddi et al.,
2008) and that specific deletion of NAPE-PLD in adipocytes of
mice decreased levels of PEA, OEA and SEA in WAT, despite
increased inflammation and influx of macrophages (Geurts
et al., 2015). In our study, HFD feeding increases the cellular
mRNA levels of the synthesizing enzymes in adipose tissue. In
addition, expansion of the total number of adipocytes in the
time course of DIO further increases whole body expression of
these enzymes. The rapid increases in gene expression in BAT
may be explained by the rapid whitening of BAT as induced by
HFD feeding (Shimizu et al., 2014). Indeed, BAT lipid droplet
content positively correlated with Nape-pld expression and AEA
plasma levels. Furthermore, these data are in line with the recent
observation that acute activation of BAT decreases Nape-pld
expression (Krott et al., 2016). Interestingly, the concentration
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of 2-AG and AEA is higher in BAT than WAT (Krott et al.,
2016), suggesting at least a role of BAT in determining
circulating endocannabinoid levels. Collectively, it is likely
that lipid-filled adipocytes rather than macrophages within the
adipose tissues contribute to circulating plasma endocannabinoid
levels.
In our study, we found no evidence for a contribution
of decreased degradation pathways of 2-AG and AEA in
adipose tissues determining plasma levels of endocannabinoids.
Specifically, we were unable to detect any expression of AEA
degradation enzyme Faah in WAT, BAT and muscle, and found
decreased liver Faah expression after 18 weeks of HFD feeding.
This is in line with the fact that FAAH was reported to play
an important role in obesity. Notably, a missense polymorphism
in the FAAH gene is associated with obesity in humans (Sipe
et al., 2005) and FAAH deficient mice have increased AEA levels
in, e.g., the liver and show increased fat mass and body weight
(Tourino et al., 2010). On the other hand, Bartelt et al. (2011)
found that HFD feeding for 16 weeks in mice caused a decrease
in Faah expression and FAAH enzymatic activity in WAT which
was accompanied by increased AEA in this tissue. To what
extend catabolism of AEA and 2-AG by adipose tissue determines
circulating levels of these endocannabinoids warrants further
study.
It is tempting to speculate on the biological role of the
increases of 2-AG and AEA in the time course of HFD-
induced obesity. Endocannabinoids are known to decrease
insulin sensitivity (Gruden et al., 2016) and to reduce sympathetic
responses by inhibiting noradrenergic signaling (Quarta et al.,
2011; Krott et al., 2016), and thereby decrease lipolysis in
WAT and thermogenesis in BAT. Possibly, in case of acute
lipid overload, as mimicked by a switch from regular chow
to a HFD, initial accumulation of lipids in WAT and BAT
drives the synthesis pathways of endocannabinoids that can
have autocrine and even paracrine effects on these organs to
inhibit sympathetic signaling. This sequence of events reduces
intracellular lipolysis in BAT and WAT, thereby resulting
in reduced thermogenesis in BAT and increased triglyceride
storage in WAT. Such as a feed-forward mechanism may
thus allow the body to store excess lipids effectively in
adipose tissues. Interestingly, we have shown that inhibition
of endocannabinoid signaling by strictly peripheral CB1R
antagonism activates BAT and reduces adiposity in HFD-
fed mice (Boon et al., 2014). In theory, HFD induced lipid
accumulation can lead to increased endocannabinoid synthesis
which attenuates BAT and WAT activity and results in a positive
energy balance.
CONCLUSION
The time course of HFD-induced obesity plasma
endocannabinoid levels rapidly rise as most probably explained
by increased synthesis pathways in adipose tissue depots. We
speculate that this sequence of events may attenuate sympathetic
signaling in these tissues by CB1R agonism, which would result
in reduced thermogenesis and increased storage of excess lipids
in WAT. Given the fact that strictly peripheral CB1R antagonism
activates BAT and reduces adiposity in mice, we anticipate that
strategies inhibiting CB1R selectively on (brown) adipocytes
or reducing endocannabinoid synthesis by adipocytes may
be a worthwhile strategy to pursue in combating obesity and
associated disorders.
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